Purpose/Objective: To compare the efficacy of external beam radiation therapy, I-125 brachytherapy, and HIFU destruction for localized Stage 1-2 prostate carcinoma. Materials and Methods: The patients with Stage 1 and 2 prostate carcinoma receiving local treatments in Samara Regional Oncological Center from October 2007 to January 2012 were chosen for analysis. The treatments were local (95% isodose to CTV) external beam 3Dconformal or intensity-modulated radiation therapy to total 74-76 Gy (EBRT), LDR brachytherapy with permanent seeds I-125 to total dose 140-145 Gy (BTI125), or HIFU ablation. Prior to HIFU all patients underwent transurethral resection of prostate. The primary endpoint was time to biochemical relapse, secondary endpoint -clinical progression free survival. The distribution by initial parameters was assessed using chi-square method. The survival comparison was made using Kaplan-Meier's curves and log-rank method. Cox regression was applied to evaluate risk factors. Results: Of 181 selected patients, 66 received EBRT, 61 -BTI125, while remaining 54 patients were treated with HIFU. Median followup, initial age, prostate volume, proportion of stage 1 and PSA level were 24, 56, 41 months; 71, 68, 69 years, 37, 32, 36 ml; 43%, 20%, 28% (p=0.017) and 10, 12, 12 ng/ml for EBRT, BTI125, and HIFU groups, respectively. Biochemical progression occurred to 25 (46%) patients after HIFU therapy, while in the EBRT group -to 11 (18%) and in BTI125 -to 16 (24%). Median time to biochemical relapse were 61.0 (95%confidence interval (CI), 55.0-67.3), 67.3 and 34.7 months, p<0.0001 for EBRT, BTI125, and HIFU, respectively. In Cox proportional hazards model after adjustment for stage, Gleason score and initial PSA, EBRT (OR 0.20, CI 95%, 0.09-0.42, p<0.0001) and BTI125 (OR 0.31, 95% CI, 0.13-0.74, p<0.0001) remained superior to HIFU by means of biochemical failure.
Conclusions:
Both external beam and interstitial radiation therapy explicit better efficacy as compared to HIFU therapy in the treatment of localized Stage 1-2 prostate carcinoma.
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Auto-delineation tools in prostate radiotherapy: a valid investment for the future? Purpose/Objective: The accurate delineation of both clinical target volumes (CTVs) and organs at risk (OARs) is crucial in modern prostate radiotherapy. However, this process is time consuming and subjected to considerable inter-clinician variation. Auto-contouring software could be one way of reducing outlining times and/or reducing interclinician variation. MIM is a commercially available atlas-based autocontouring software package and the aims of this study are to determine whether MIM can reduce intra-clinician variability and delineation times for prostate cancer. Materials and Methods: Five cases of locally advanced prostate cancer were randomly selected and seven clinicians were asked to delineate CTVs and OARs using a set of delineation guidelines. Total time required for delineation was recorded using a stop watch. A MIM atlas of 50 patients was prepared and stratified according to bladder volumes. The MIM software (version 5.1) was then used to autocontour the 5 original cases and clinicians were asked to edit the auto-contoured structures and record delineation/correction times. The intra-clinician variation was assessed using conformity level (CL). The CL and delineation times were compared with and without MIM using a paired t-test. Results: The CL pre-MIM of CTV1 varied from 0.40-0.60 (mean 0.52) and CTV2 between 0.50-0.61 (mean 0.52). There was no significant improvement in CL using MIM software for CTV1 (mean 0.54, p=0.44) and CTV2 (mean 0.56, p=0.22). Mean bladder CL improved from 0.68 to 0.74 (p=0.04) with no improvement for other OARs. The delineation times were not significantly shorter using MIM software except the right hip (table 1) , but varied between clinicians (figure 1). post-prostatectomy biochemical recurrence, n=15; post-brachytherapy biochemical recurrence, n=2; and post-prostatectomy adjuvance, n=5). The dose prescribed to the prostate ranged between 72-78Gy, except for one case (post-brachytherapy recurrence, 66Gy) with conventional fractionation (2Gy/fraction). The seminal vesicles received between 50-56Gy, the surgical bed 66-74Gy, and the pelvic lymph nodes 46-50.4Gy (n=20), respectively when applicable, with conventional fractionation. Genitourinary (GU) and gastrointestinal (GI) toxicity was scored using the Radiation Therapy Oncology Group (RTOG) scoring system. Potential risk factors for toxicity were assessed in univariate and multivariate logistic regression analysis. Results: The median age was 68 years (range 51-87 years). The median follow-up was 37 months (range 3-74 months). The mean initial Gleason score was 6 and the mean initial PSA was 17 ng/ml. For patients with a primary diagnosis or those receiving adjuvant HT, median overall survival was 45 months (range, 8-82 months) . For patients receiving HT for biochemical recurrence, overall survival was 24 months (range, 3-73 months). Overall, only 3 patients died, and none of them due to a cancer-related cause. Local recurrence was seen in 1 patient which had been treated for a biochemical recurrence after initial prostatectomy. Purpose/Objective: The aim of the present study was to evaluate the prevalence and severity of lower limb lymphedema after pelvic lymphadenectomy and radiotherapy to the pelvic lymph nodes in patients with prostate cancer. Materials and Methods: Twenty-six patients underwent combined treatment for high-risk node positive prostate cancer at the department of oncology at Skåne University Hospital between April 2008 and March 2011. The treatment consisted of pelvic lymphadenectomy followed by androgen deprivation therapy and radiotherapy to the pelvic lymph nodes and prostate. The pelvic nodes, prostate and seminal vesicles were treated with external beam radiotherapy (EBRT) to an absorbed dose of 50 Gy followed by a brachytherapy boost of 2*10 Gy to the prostate only. Twenty-two patients accepted an invitation to a clinical examination with focus on lower limb swelling. The time between RT and examination was median 2.4 years (range 1.2-4.1 y). Results: Six patients (27%) experienced grade 1 lymphedema and two patients (9%) grade 2 while none had grade 3 or 4 according to the CTC Common Toxicity Criteria scale 4.0. Three patients required treatment with compression socks. Conclusions: Brachytherapy and pelvic EBRT have a low incidence of lymphedema in patients with high risk node positive prostate cancer that have undergone pelvic lymph node dissection. The follow-up time is however short and patients need to be followed for a longer period of time.
